Funding for this research was provided by:
US National Institutes of Health (R25T CA112355, R01 CA201358)
Received: 29 May 2020
Accepted: 7 October 2020
First Online: 27 October 2020
Ethics approval and consent to participate
: This research was conducted with approved access to UK Biobank data under application number 14105 (PI: Witte). All UK Biobank participants provided informed consent at recruitment. The UK Biobank has been developed as a research resource that relies on a broad consent model. Research using UK Biobank data is conducted in accordance with the UK Biobank Ethics and Governance Framework, which sets specific standards for this resource so that all necessary safeguards are in place to ensure that the data and samples are only used for scientifically and ethically approved research. Ethics approval for the UK Biobank study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382).
: Not applicable.
: J.S.W. is a non-employee co-founder of Avail.bio and serves as an expert witness for Pfizer and Sanofi. The remaining authors declare that they have no competing interests.